| HOME >> BIOLOGY >> TECHNOLOGY |
Contact:
Glenn Schulman, PharmD
Director of Investor Relations
(888) 436-6642
CURAGEN CORPORATION AND SUBSIDIARY
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
(unaudited) (unaudited)
Collaboration revenue $22 $14 $88 $2,298
Operating expenses:
Research and development 6,299 10,870 36,779 44,009
General and administrative 2,026 3,362 11,657 13,648
Restructuring charges 2,737 - 11,274 -
Total operating expenses 11,062 14,232 59,710 57,657
Loss from operations (11,040) (14,218) (59,622) (55,359)
Interest income 1,474 1,718 5,534 7,170
Interest expense (995) (2,332) (5,167) (9,351)
Realized (loss)/gain on sale of
available-for-sale investments,
net (308) - 665 -
Gain on extinguishment of debt 8,273 - 8,442 -
Loss from continuing operations
before income tax benefit (2,596) (14,832) (50,148) (57,540)
Income tax benefit 25 215 185 376
Loss from continuing operations (2,571) (14,617) (49,963) (57,164)
Discontinued operations:
Loss from discontinued
operation
'/>"/>
| SOURCE CuraGen Corporation Copyright©2008 PR Newswire. All rights reserved |